BeiGene (ONC) Stock Forecast & Price Target

Compare

776 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ONC Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

BeiGene

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$335.18

▲(31.00%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for BeiGene in the last 3 months. The average price target is $335.18 with a high forecast of $359.47 and a low forecast of $300.00. The average price target represents a 31.00% change from the last price of $255.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"143":"$143","360":"$360","197.25":"$197.3","251.5":"$251.5","305.75":"$305.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":359.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$359.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":335.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$335.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$300.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[143,197.25,251.5,305.75,360],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,245.93,254.66384615384615,263.3976923076923,272.13153846153847,280.86538461538464,289.59923076923076,298.33307692307693,307.0669230769231,315.8007692307692,324.5346153846154,333.26846153846157,342.0023076923077,350.73615384615385,{"y":359.47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,245.93,252.79538461538462,259.66076923076923,266.5261538461539,273.39153846153846,280.2569230769231,287.1223076923077,293.9876923076923,300.8530769230769,307.71846153846155,314.58384615384614,321.4492307692308,328.3146153846154,{"y":335.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,245.93,250.08923076923077,254.24846153846156,258.4076923076923,262.5669230769231,266.72615384615386,270.8853846153846,275.0446153846154,279.20384615384614,283.3630769230769,287.52230769230766,291.6815384615385,295.84076923076924,{"y":300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":148.85,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.89,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$359.47

Average Price Target$335.18

Lowest Price Target$300.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$245

Hold

-4.24%

Downside

Reiterated

05/20/25

BeiGene's overall stock score reflects a mix of strong revenue growth and market leadership, especially highlighted by their recent achievement of GAAP profitability. However, persistent operational costs and negative free cash flow remain concerns. The stock's technical indicators and valuation metrics suggest caution, with the stock currently experiencing weak momentum and a lack of profitability. The company's strategic investments and pipeline advancements are significant strengths, positioning it well for future growth.

Rebecca LiangBernstein

Bernstein

―

Hold

―

Reiterated

06/05/25

Bernstein Reaffirms Their Hold Rating on BeiGene (ONC)

David LiBank of America Securities

Bank of America Securities

$320→$300

Buy

17.25%

Upside

Reiterated

05/26/25

BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating

Jill WuCMB International Securities

CMB International Securities

$359.47

Buy

40.49%

Upside

Reiterated

05/08/25

BeiGene's Strong Market Position and Promising Financial Outlook Drive Buy Rating

Andrew BerensLeerink Partners

Leerink Partners

$310→$334

Buy

30.54%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Michael SchmidtGuggenheim

Guggenheim

$348→$350

Buy

36.79%

Upside

Reiterated

05/07/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Generation Bio (GBIO)

Gregory RenzaRBC Capital

RBC Capital

$312→$311

Buy

21.55%

Upside

Reiterated

05/07/25

RBC Capital Reaffirms Their Buy Rating on BeiGene (ONC)

Yaron WerberTD Cowen

TD Cowen

$334

Buy

30.54%

Upside

Reiterated

05/07/25

BeiGene's Strong Market Position and Growth Potential Affirmed by Buy Rating

Reni BenjaminCitizens JMP

Citizens JMP

$348

Buy

36.01%

Upside

Reiterated

04/04/25

BeiGene's Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin

Unknown AnalystCiti

Not Ranked

Citi

$345

Buy

34.84%

Upside

Reiterated

03/13/25

We maintain Buy. TP $345.

Jessica FyeJ.P. Morgan

J.P. Morgan

$311

Buy

21.55%

Upside

Reiterated

02/28/25

BeiGene (ONC) Gets a Buy from J.P. Morgan

Tony RenMacquarie

Macquarie

$259→$313

Buy

22.33%

Upside

Reiterated

02/28/25

BeiGene price target raised to $313 from $259 at MacquarieBeiGene price target raised to $313 from $259 at Macquarie

Sean LaamanMorgan Stanley

Morgan Stanley

$300→$317

Buy

23.90%

Upside

Reiterated

02/28/25

BeiGene (ONC) Receives a Buy from Morgan Stanley

Kelly ShiJefferies

Jefferies

$286

Buy

11.78%

Upside

Reiterated

02/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BeiGene (NASDAQ: ONC) and AptarGroup (NYSE: ATR)

Matthew YanCLSA

CLSA

$248.4→$263.1

Buy

2.83%

Upside

Reiterated

11/13/24

BeiGene, Ltd. (BGNE) PT Raised to $263.10 at CLSACLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $263.10 (from $248.40) while maintaining a Outperform (2) rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$245

Hold

-4.24%

Downside

Reiterated

05/20/25

Rebecca LiangBernstein

Bernstein

―

Hold

―

Reiterated

06/05/25

Bernstein Reaffirms Their Hold Rating on BeiGene (ONC)

David LiBank of America Securities

Bank of America Securities

$320→$300

Buy

17.25%

Upside

Reiterated

05/26/25

BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating

Jill WuCMB International Securities

CMB International Securities

$359.47

Buy

40.49%

Upside

Reiterated

05/08/25

BeiGene's Strong Market Position and Promising Financial Outlook Drive Buy Rating

Andrew BerensLeerink Partners

Leerink Partners

$310→$334

Buy

30.54%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Michael SchmidtGuggenheim

Guggenheim

$348→$350

Buy

36.79%

Upside

Reiterated

05/07/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Generation Bio (GBIO)

Gregory RenzaRBC Capital

RBC Capital

$312→$311

Buy

21.55%

Upside

Reiterated

05/07/25

RBC Capital Reaffirms Their Buy Rating on BeiGene (ONC)

Yaron WerberTD Cowen

TD Cowen

$334

Buy

30.54%

Upside

Reiterated

05/07/25

BeiGene's Strong Market Position and Growth Potential Affirmed by Buy Rating

Reni BenjaminCitizens JMP

Citizens JMP

$348

Buy

36.01%

Upside

Reiterated

04/04/25

BeiGene's Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin

Unknown AnalystCiti

Not Ranked

Citi

$345

Buy

34.84%

Upside

Reiterated

03/13/25

We maintain Buy. TP $345.

Jessica FyeJ.P. Morgan

J.P. Morgan

$311

Buy

21.55%

Upside

Reiterated

02/28/25

BeiGene (ONC) Gets a Buy from J.P. Morgan

Tony RenMacquarie

Macquarie

$259→$313

Buy

22.33%

Upside

Reiterated

02/28/25

BeiGene price target raised to $313 from $259 at MacquarieBeiGene price target raised to $313 from $259 at Macquarie

Sean LaamanMorgan Stanley

Morgan Stanley

$300→$317

Buy

23.90%

Upside

Reiterated

02/28/25

BeiGene (ONC) Receives a Buy from Morgan Stanley

Kelly ShiJefferies

Jefferies

$286

Buy

11.78%

Upside

Reiterated

02/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BeiGene (NASDAQ: ONC) and AptarGroup (NYSE: ATR)

Matthew YanCLSA

CLSA

$248.4→$263.1

Buy

2.83%

Upside

Reiterated

11/13/24

BeiGene, Ltd. (BGNE) PT Raised to $263.10 at CLSACLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $263.10 (from $248.40) while maintaining a Outperform (2) rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeiGene

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+2.59%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +2.59% per trade.

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+11.36%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +11.36% per trade.

1 Year

Kelly ShiJefferies

Success Rate

14/14 ratings generated profit

Average Return

+22.26%

reiterated a buy rating 4 months ago

Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.26% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+36.63%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ONC has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 335.18.

Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $0.21 with a range of -$0.28 to $1.43. The previous quarter’s EPS was $0.00. ONC beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ONC has Outperformed its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.23B with a range of $1.21B to $1.27B. The previous quarter’s sales results were $1.12B. ONC beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year ONC has Outperformed its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?

Based on analyst ratings, BeiGene’s 12-month average price target is 335.18.

What is ONC’s upside potential, based on the analysts’ average price target?

BeiGene has 31.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ONC a Buy, Sell or Hold?

BeiGene has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is BeiGene’s price target?

The average price target for BeiGene is 335.18. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $359.47 ,the lowest forecast is $300.00. The average price target represents 31.00% Increase from the current price of $255.86.

What do analysts say about BeiGene?

BeiGene’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ONC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BeiGene (ONC) Stock Forecast & Price Target

ONC Analyst Ratings

ONC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BeiGene

ONC Analyst Recommendation Trends

ONC Financial Forecast

ONC Earnings Forecast

ONC Sales Forecast

ONC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts